Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor

J Cyst Fibros. 2023 Nov;22(6):1130-1132. doi: 10.1016/j.jcf.2023.06.013. Epub 2023 Jul 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aminophenols / adverse effects
  • Benzodioxoles / adverse effects
  • Chloride Channel Agonists / adverse effects
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / drug therapy
  • Cystic Fibrosis* / genetics
  • Drug Combinations
  • Gilbert Disease* / diagnosis
  • Gilbert Disease* / drug therapy
  • Gilbert Disease* / genetics
  • Humans
  • Hyperbilirubinemia
  • Mutation

Substances

  • elexacaftor
  • ivacaftor
  • tezacaftor
  • Aminophenols
  • Benzodioxoles
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Chloride Channel Agonists
  • Drug Combinations